https://drugchannels.net

Drug ChannelsDrug Channels Pages ABOUT INDUSTRY REPORTS WEBINARS KEYNOTE SPEAKING ADVERTISE SUBSCRIBE / CONTACT Drug Channels delivers timely analysis and provocative opinions from Adam J. Fein, Ph.D., the country's foremost expert on pharmaceutical economics and the drug distribution system. Drug Channels reaches an engaged, loyal and growing audience of nearly 100,000 subscribers and followers. Learn more... Wednesday, September 11, 2024 White Bagging Update 2024: Providers’ Pushback Preserves Buy-and-Bill Time for DCI’s annual update on the channels for provider-administered drugs. Below, I review the latest data on 2024 trends and compare them to the pre-pandemic figures. For 2024, payers report that specialty pharmacies—via white and clear bagging—have displaced buy-and-bill for a meaningful share of commercial covered lives utilizing provider-administered oncology drugs. However, provider pushback has limited specialty pharmacies' share gains, so that buy-and-bill remains the most common channel for these products. Payers’ adoption of white bagging—and provider’s push back—reflect the ongoing battle for oncology margin in U.S. drug channels. Let’s hope that patients don’t get caught in the crossfire. P.S. Today’s article is adapted from Chapter 3 of DCI’s forthcoming 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, which will be available to preorder next week at special introductory pricing. Read more » Posted by Adam J. Fein, Ph.D. on Wednesday, September 11, 2024 No comments: Labels: Benefit Design, Buy-and-Bill, Channel Management, Hospitals, Pharmacy, Physicians, Specialty Drugs Tuesday, September 10, 2024 Drug Channels Leadership Forum: Full Agenda Now Available (Spoiler: It’s Awesome!) I am pleased to announce the full agenda for the inaugural Drug Channels Leadership Forum, which will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. Everyone here at Drug Channels Institute (DCI) is excited to bring this novel event to the drug channels community. I personally assembled the agenda. As you can see, it’s filled with senior industry executives who will participate in fireside chats with me as well as topical panel discussions moderated by a diverse set of subject matter experts. Check out our fantastic lineup of speakers View the full Drug Channels Leadership Forum agenda I am also pleased to announce an excellent addition to the agenda. David Joyner, Executive Vice President, CVS Health, and President, CVS Caremark, and Prem Shah, Executive Vice President and Chief Pharmacy Officer, CVS Health and President, Pharmacy and Consumer Wellness, will be joining me for a fireside chat. To maximize the value of networking and learning, the event will have fewer than 450 participants. If you haven’t done so yet, click here to request an invitation. DCI will carefully review all submissions to include participants from a broad range of industry organizations. DCI will begin extending invitations on a rolling basis starting on September 23, 2024. Once you receive your invitation, you will have 15 business days to accept and complete the registration by paying the registration fee. Please note that the number of attendees from technology companies, business services, and other industry vendors will be strictly limited to the number of badges included with their chosen sponsorship level. There will be no exhibit hall and no media. Click here to learn more about available sponsorship opportunities. Visit the event website for more information on the registration process and our policies. Read on for the full press release. I hope you can join us! Read more » Posted by Adam J. Fein, Ph.D. on Tuesday, September 10, 2024 No comments: Labels: DCI In-Person Events, Industry Trends Friday, September 06, 2024 Three Areas to Watch: The Inflation Reduction Act and Prescription Pricing Today’s guest post comes from H. John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds John discusses how the new maximum fair prices (MFPs) published by the Centers for Medicaid & Medicare Services (CMS) will affect medication affordability, formulary negotiations, evidence-based strategies, and other aspects of the market. To learn more, register for CoverMyMeds' October 10, 2024, webinar: The Inflation Reduction Act: What to Watch Following the First Round of Negotiations. Read on for John’s Insights. Read more » Posted by Adam J. Fein, Ph.D. on Friday, September 06, 2024 No comments: Labels: Guest Post, Sponsored Post Wednesday, September 04, 2024 Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? The Humira biosimilar market just took another step forward—but remains far from its ideal state. Last week, Cigna’s Express Scripts announced that it that will follow CVS Health’s CVS Caremark business and remove Humira from its largest commercial formulary in favor of multiple biosimilars. Below, we review the 19 products competing with Humira—including four private-label products marketed by in-house subsidiaries owned by CVS Health and Cigna.As you will see below, CVS Health’s formulary actions led to rapid uptake of a low-list-price biosimilar. Express Scripts’ 2025 strategy will also drive biosimilar adoption, although its pricing strategy is more problematic. But what’s really going to bake your noodle later: Would the largest PBMs have popped the gross-to-net bubble for Humira if they hadn’t been able to profit from the switch? Read more » Posted by Adam J. Fein, Ph.D. on Wednesday, September 04, 2024 No comments: Labels: Benefit Design, Biosimilars, Gross-to-Net Bubble, PBMs, Specialty Drugs Tuesday, September 03, 2024 The Healthcare Innovation Company's Value-Based Care Summit The Healthcare Innovation Company's Value-Based Care Summit In-Person Event | October 28 - 29, 2024 in Washington, DC Use promo code VBCDC to save $100. Register Today. Download the brochure. The Value-Based Care Summit, produced by The Healthcare Innovation Company (thINc), brings together healthcare providers, health plans, pharmaceutical companies/manufacturers, and regulatory and legislative leaders to discuss novel approaches, innovative models, and mutually beneficial partnerships that drive care delivery transformation and accelerate the transition to value-based care. Can't miss content highlights including: Risk-Sharing and Value-Based Contracting: Examine outcomes-based strategies and innovations in value-based contracting arrangements Policy and Regulations: Understand key updates from policy experts including HHS and CMS on value-based payment models Value-Based Digital Solutions: Explore case studies on how to test, design, and scale digital services Cross-Stakeholder Partnerships: Foster stakeholder partnerships to optimize patient support and care delivery Population Health and Value-Based Care: Leverage real-world data and understand social determinants of health to build predictive value-based care solutions for populations Must-attend sessions include: Enhancing Value-Driven Care through Patient Engagement, Customer Experience, and Quality Measurement Jennifer Norton, SVP of US Patient and Market Access (PAMA), Takeda Pharmaceuticals Leadership Roundtable: Transformational Leadership Strategies for Driving Value Lee J. Handke, PharmD, MBA, CEO, Nebraska Health Network Conrad Vial, MD, SVP, Sutter Health and President, Sutter Health Network Moderator: Josh Berlin, JD, CEO, rule of three, LLC Key Strategies from the Value-Based Care Playbook Mollie Gelburd, JD, Senior Director, Delivery System & Payment Transformation, America's Health Insurance Plans (AHIP) Aisha Pittman, MHP, SVP of Government Affairs, National Association of ACOs (NAACOS) Jeff Micklos, Executive Director, Healthcare Transformation Task Force Carol Vargo, VP, Physician Practice Sustainability, The American Medical Association (AMA) Moderator: Debbie Welle-Powell, MPA, Adjunct Professor, University of Colorado Business School; Past Chair, National Association of ACOs (NAACOS); CEO, DWP Advisors PLUS! Two Dedicated Tracks for Your Focus Area: Data Analytics and Technology Strategy and Operations View the current Speaker Faculty and register today. Bonus content for Pharma and Life Sciences executives: You can attend the Specialty Networks and Patient Support Services Summit, October 29-30 in the same venue. *All registrations subject to review by the thINc team. Promo codes are only applicable to NEW registrations and not applicable for vendors/solutions providers. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net). Posted by Adam J. Fein, Ph.D. on Tuesday, September 03, 2024 No comments: Labels: Sponsored Post Friday, August 23, 2024 Embedding Into the Provider’s Workflow is Key to a Specialty Drug’s Success Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Nasir reviews the cumbersome processes that affect providers’ preferences when prescribing a specialty drug to their patients. He believes that embedding the specialty drug initiation process into the provider’s workflow will benefit both patients and prescribers. Learn more by downloading CareMetx’s new 2024 Patient Services Report: Revealing Manufacturer Priorities: Patients Naturally Take Center Stage. Read on for Nasir’s Insights. Read more » Posted by Adam J. Fein, Ph.D. on Friday, August 23, 2024 No comments: Labels: Guest Post, Sponsored Post Tuesday, August 20, 2024 Drug Channels News Roundup, August 2024: My $0.02 on the IRA’s MFPs, UNC’s New PBM, Amazon vs. Retail, Fixing 340B, and Mark Cuban Lets Loose Another news-laden summer is ending. Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Jersey shore: Some uncomfortable realities of the Inflation Reduction Act’s (IRA’s) first set of 10 prices Amazon goes after retail pharmacies with an amusing lack of self-awareness A health system-backed start-up pharmacy benefit manager (PBM) will somehow deliver massive drug costs savings An intriguing solution for fixing the 340B program Plus, Mark Cuban unloads on the healthcare system during an entertaining interview. P.S. Join my nearly 58,000 LinkedIn followers for daily links to neat stuff along with thoughtful and provocative commentary from the DCI community. Have you requested an invite to the inaugural Drug Channels Leadership Forum? Attendance will be highly limited, so apply now. Full agenda coming soon! Read more » Posted by Adam J. Fein, Ph.D. on Tuesday, August 20, 2024 No comments: Labels: 340B, Hospitals, Inflation Reduction Act of 2022, PBMs, Pharmacy Friday, August 16, 2024 When Payers Become Producers: Inside the PBM Private-Labeling Trend Today’s guest post comes from Benjamin Hinton II, Senior Market Access Solutions Analyst at MMIT. Benjamin reviews the growing trend of PBMs vertically integrating into the production of biosimilars. He shares data from an MMIT survey of 20 large national payers, independent plans, Blues affiliates and PBMs (excluding participants). The findings shed light on payers' view of biosimilar conpetition, contracting challenges, and other issues. Click here to learn more about MMIT’s Custom Market Research offering for biosimilar manufacturers. Read on for Benjamin’s insights. Read more » Posted by Adam J. Fein, Ph.D. on Friday, August 16, 2024 No comments: Labels: Guest Post, Sponsored Post Tuesday, August 13, 2024 Can Rite Aid Recover? Last fall, poor ol’ Rite Aid finally succumbed to bankruptcy. It was pretty much the definition of an expected surprise. To get a comprehensive look at the company’s ever-declining fortunes, DCI rummaged around the compnay's numerous bankruptcy filings. Below, you’ll find our review of Rite Aid’s current financial situation, shrinking store footprint, changing relationship with key wholesaler McKesson, surprisingly optimistic projections, and more. Drug Channels has been tracking retail pharmacies’ economic and business challenges—and Rite Aid’s troubles—for many years. Consider this article to be an opportunity for some fact-based analysis to replace your schadenfreude. Read more » Posted by Adam J. Fein, Ph.D. on Tuesday, August 13, 2024 No comments: Labels: Channel Management, Pharmacy, Pharmacy Economics, Wholesalers Friday, August 09, 2024 IRA Reality Check: Four Strategies for Adapting Hub and Copay Programs Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Chris reviews recent developments for the Inflation Reduction Act of 2022 (IRA). He then recommends four IRA-related adjustments that manufacturers should make to their patient support programs. To learn more, register for ConnectiveRx’s free webinar on September 17: IRA Reality Check: Adapting Hub and Copay Programs to Ensure Patient Access and Affordability. Read on for Chris’s insights. Read more » Posted by Adam J. Fein, Ph.D. on Friday, August 09, 2024 No comments: Labels: Guest Post, Sponsored Post Tuesday, August 06, 2024 Follow the 340B Prescription Dollar: How PBMs Profit from 340B Contract Pharmacies (Video) In my recent The 340B Drug Pricing Program: Trends, Controversies, and Outlook video webinar, I provided an update on the economics of the 340B program, reviewed the multiple controversies surrounding the program’s operations, discussed state and federal legislation, and analyzed how the Inflation Reduction Act of 2022 (IRA) will alter the 340B market.In the video excerpt below, I walk through a brief history of 340B contract pharmacies. I then document how five multi-billion-dollar, for-profit, publicly traded pharmacy chains and pharmacy benefit managers (PBMs)—Cigna (via Express Scripts), CVS Health, UnitedHealth Group (via OptumRx), and Walgreens, Walmart—continue to dominate the 340B contract pharmacy market. I conclude with a “follow the dollar” example of 340B prescription economics with contract pharmacies.If this clip whets your appetite for more, register to watch a replay of the full 90-minute video webinar from June.You can also check out our recent data deep dive: Hospitals Are Relying More on PBMs to Manage Manufacturers' 340B Contract Pharmacy Restrictions: DCI's 2024 Market Analysis.Click here if you can’t see the video below. Posted by Adam J. Fein, Ph.D. on Tuesday, August 06, 2024 No comments: Labels: 340B, Hospitals, PBMs, Pharmacy, Pharmacy Economics, Specialty Drugs, Video Friday, August 02, 2024 Mid-Year Hub Review: Five Considerations for Staying Ahead of the Curve Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx. Stacey provides five crucial questions to help life science companies evaluate providers of patient support programs (PSPs). To learn more, register for AssistRx's free three-part webinar series: Ahead of the Curve: Considerations for your 2025 Patient Support Program. Read on for Stacey’s insights. Read more » Posted by Adam J. Fein, Ph.D. on Friday, August 02, 2024 No comments: Labels: Guest Post, Sponsored Post Older Posts Home Drug Channels is written by Adam J. Fein, Ph.D. Dr. Fein is President of Drug Channels Institute, an HMP Global company. Read More... Email Dr. FeinFollow on LinkedIn@DrugChannelsDrug Channels videos PURCHASE OUR INDUSTRY REPORTS Sponsors Search Drug Channels View Articles by Topic Select a Topic 340B Accountable Care Organizations (ACOs) Alternative Funding Programs (AFPs) Average Acquisition Cost (AAC) Average Manufacturer Price (AMP) Average Sales Price (ASP) Benefit Design Biosimilars Blog Administration Book Review Buy-and-Bill Cell and Gene Therapies Channel Management Co-pay Offset Programs Copay Accumulator Adjustment Costs/Reimbursement COVID-19 DCI In-Person Events Digital Pharmacy Direct and Indirect Remuneration (DIR) Discount Cards Drug Counterfeiting Drug Shortages Enforcement Fun Stuff Generic Drugs Gross-to-Net Bubble Group Purchasing Organizations (GPOs) Guest Post Health Care Policy Health Care Reform Health Insurance Exchanges Health Maintenance Organizations (HMOs) Hospitals Importation Industry Trends Inflation Reduction Act of 2022 International Drug Channels Marketing Medicaid Medicare Part D Mergers and Acquisitions Narrow Networks Patient Perspective PBMs Pedigree Pharmacogenomics Pharmacy Pharmacy Economics Physicians Retail Clinics RFID Specialty Drugs Sponsored Post Supply Chain Humor Supply Chain Technology Video Wholesalers Popular Recent Posts Drug Channels News Roundup, August 2024: My $0.02 on the IRA’s MFPs, UNC’s New PBM, Amazon vs. Retail, Fixing 340B, and Mark Cuban Lets Loose Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? Can Rite Aid Recover? When Payers Become Producers: Inside the PBM Private-Labeling Trend Three Areas to Watch: The Inflation Reduction Act and Prescription Pricing View Articles by Date ▼  2024 (85) ▼  September 2024 (5) White Bagging Update 2024: Providers’ Pushback Pre... Drug Channels Leadership Forum: Full Agenda Now Av... Three Areas to Watch: The Inflation Reduction Act ... Humira Biosimilar Price War Update: Should We Be G... The Healthcare Innovation Company's Value-Based Ca... ►  August 2024 (7) ►  July 2024 (8) ►  June 2024 (12) ►  May 2024 (9) ►  April 2024 (14) ►  March 2024 (12) ►  February 2024 (9) ►  January 2024 (9) ►  2023 (127) ►  December 2023 (10) ►  November 2023 (7) ►  October 2023 (15) ►  September 2023 (12) ►  August 2023 (10) ►  July 2023 (7) ►  June 2023 (13) ►  May 2023 (11) ►  April 2023 (8) ►  March 2023 (16) ►  February 2023 (9) ►  January 2023 (9) ►  2022 (126) ►  December 2022 (11) ►  November 2022 (8) ►  October 2022 (10) ►  September 2022 (10) ►  August 2022 (9) ►  July 2022 (14) ►  June 2022 (10) ►  May 2022 (8) ►  April 2022 (15) ►  March 2022 (12) ►  February 2022 (10) ►  January 2022 (9) ►  2021 (128) ►  December 2021 (10) ►  November 2021 (9) ►  October 2021 (11) ►  September 2021 (14) ►  August 2021 (9) ►  July 2021 (9) ►  June 2021 (15) ►  May 2021 (10) ►  April 2021 (12) ►  March 2021 (14) ►  February 2021 (4) ►  January 2021 (11) ►  2020 (132) ►  December 2020 (9) ►  November 2020 (11) ►  October 2020 (15) ►  September 2020 (15) ►  August 2020 (10) ►  July 2020 (11) ►  June 2020 (6) ►  May 2020 (12) ►  April 2020 (9) ►  March 2020 (14) ►  February 2020 (11) ►  January 2020 (9) ►  2019 (148) ►  December 2019 (11) ►  November 2019 (11) ►  October 2019 (16) ►  September 2019 (10) ►  August 2019 (14) ►  July 2019 (15) ►  June 2019 (10) ►  May 2019 (14) ►  April 2019 (15) ►  March 2019 (10) ►  February 2019 (12) ►  January 2019 (10) ►  2018 (158) ►  December 2018 (13) ►  November 2018 (13) ►  October 2018 (14) ►  September 2018 (12) ►  August 2018 (14) ►  July 2018 (12) ►  June 2018 (15) ►  May 2018 (13) ►  April 2018 (15) ►  March 2018 (13) ►  February 2018 (12) ►  January 2018 (12) ►  2017 (155) ►  December 2017 (13) ►  November 2017 (12) ►  October 2017 (12) ►  September 2017 (11) ►  August 2017 (13) ►  July 2017 (14) ►  June 2017 (14) ►  May 2017 (17) ►  April 2017 (14) ►  March 2017 (13) ►  February 2017 (11) ►  January 2017 (11) ►  2016 (155) ►  December 2016 (12) ►  November 2016 (13) ►  October 2016 (14) ►  September 2016 (11) ►  August 2016 (15) ►  July 2016 (13) ►  June 2016 (12) ►  May 2016 (12) ►  April 2016 (16) ►  March 2016 (13) ►  February 2016 (14) ►  January 2016 (10) ►  2015 (157) ►  December 2015 (9) ►  November 2015 (12) ►  October 2015 (14) ►  September 2015 (14) ►  August 2015 (12) ►  July 2015 (15) ►  June 2015 (11) ►  May 2015 (13) ►  April 2015 (15) ►  March 2015 (15) ►  February 2015 (14) ►  January 2015 (13) ►  2014 (148) ►  December 2014 (11) ►  November 2014 (10) ►  October 2014 (15) ►  September 2014 (13) ►  August 2014 (15) ►  July 2014 (13) ►  June 2014 (13) ►  May 2014 (10) ►  April 2014 (16) ►  March 2014 (10) ►  February 2014 (11) ►  January 2014 (11) ►  2013 (147) ►  December 2013 (11) ►  November 2013 (11) ►  October 2013 (13) ►  September 2013 (15) ►  August 2013 (9) ►  July 2013 (11) ►  June 2013 (12) ►  May 2013 (10) ►  April 2013 (16) ►  March 2013 (14) ►  February 2013 (11) ►  January 2013 (14) ►  2012 (145) ►  December 2012 (10) ►  November 2012 (11) ►  October 2012 (14) ►  September 2012 (11) ►  August 2012 (15) ►  July 2012 (13) ►  June 2012 (13) ►  May 2012 (12) ►  April 2012 (13) ►  March 2012 (10) ►  February 2012 (12) ►  January 2012 (11) ►  2011 (137) ►  December 2011 (8) ►  November 2011 (9) ►  October 2011 (12) ►  September 2011 (14) ►  August 2011 (13) ►  July 2011 (10) ►  June 2011 (11) ►  May 2011 (15) ►  April 2011 (11) ►  March 2011 (12) ►  February 2011 (11) ►  January 2011 (11) ►  2010 (139) ►  December 2010 (8) ►  November 2010 (12) ►  October 2010 (11) ►  September 2010 (13) ►  August 2010 (12) ►  July 2010 (10) ►  June 2010 (16) ►  May 2010 (11) ►  April 2010 (13) ►  March 2010 (12) ►  February 2010 (10) ►  January 2010 (11) ►  2009 (108) ►  December 2009 (11) ►  November 2009 (10) ►  October 2009 (14) ►  September 2009 (12) ►  July 2009 (2) ►  June 2009 (10) ►  May 2009 (11) ►  April 2009 (10) ►  March 2009 (10) ►  February 2009 (9) ►  January 2009 (9) ►  2008 (94) ►  December 2008 (6) ►  November 2008 (5) ►  October 2008 (9) ►  September 2008 (15) ►  August 2008 (1) ►  July 2008 (2) ►  June 2008 (13) ►  May 2008 (9) ►  April 2008 (9) ►  March 2008 (8) ►  February 2008 (9) ►  January 2008 (8) ►  2007 (115) ►  December 2007 (8) ►  November 2007 (13) ►  October 2007 (10) ►  September 2007 (13) ►  August 2007 (7) ►  July 2007 (16) ►  June 2007 (7) ►  May 2007 (8) ►  April 2007 (6) ►  March 2007 (9) ►  February 2007 (7) ►  January 2007 (11) ►  2006 (57) ►  December 2006 (7) ►  November 2006 (9) ►  October 2006 (9) ►  September 2006 (10) ►  August 2006 (5) ►  July 2006 (5) ►  June 2006 (8) ►  May 2006 (4) Drug Channels in the News Drug Channels Leadership Forum to feature powerhouse lineup in event hosted by HMP Global’s Drug Channels Institute EIN PresswireFederal agency opposes J&J's new 340B discount model, promises to take 'actions as warranted' Endpoints The Next 340B Battle: Discount Duplication With Medicare Negotiated Prices The Pink SheetThe Anti-Competitive Middlemen Harming Pharmacies And Patients ForbesIRA Could ‘Crush the 340B Margin,’ Force Transparency into Program, Says Adam Fein of Drug Channels 340B ReportThe Opaque Industry Secretly Inflating Prices for Prescription Drugs The New York TimesNavigating the Inflation Reduction Act's Impact on Drug Pricing and Health Care First Report Managed CareBiden’s War on Medicare RealClear PolicyMedicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene? The Pink SheetBoehringer Ingelheim to cap asthma inhaler out-of-pocket costs at $35 STATLatest Formulary Exclusions from Top PBMs Demonstrate Issues in the Drug Pricing Landscape First Report Managed CareDrug Channel Entities Are Undergoing Raft of Changes Spotlight on Market AccessCVS Removes Humira From Formulary — But the Fine Print Is Key Radar on Drug BenefitsCVS Plans to Overhaul How Much Drugs Cost The Wall Street JournalCigna-Humana Merger Is Likely to Face Antitrust Challenge The Wall Street JournalAmazon Once Inspired Fear in the Health-Care Industry. No Longer BloombergWhy Your Neighborhood Pharmacy Isn’t So Friendly Anymore The Wall Street JournalRite Aid Bankruptcy Follows Years of PBM Misadventure Radar on Drug BenefitsWhat CVS Stands to Gain by Setting Up Biosimilar Subsidiary Cordavis MedCity NewsOhio senator says Medicare drug cost negotiations will save money. Others aren't so sure WSYXDrug Benefit Firms Devise New Fees That Go to Them, Not Clients BloombergCVS Health Dives As Blue Shield Of California Taps Mark Cuban, Amazon In Challenge To PBM Model Investor's Business DailyA Big Health Insurer Is Ripping Up the Playbook on Drug Pricing The Wall Street JournalPatients already paying price for PBMs diverting copay cash meant for needy ABC6PBMs Keep New Biosimilars on Equal Footing With Best-Selling Humira, Radar on Drug BenefitsAccumulators, Maximizers, Alternative Funding Models Contribute to ‘Doom Loop of Specialty Drug Benefits’ AIS HealthHow to Beat the Rising Cost of Prescription Drugs Consumer ReportsAverage salaries for retail pharmacists grows for first time in three years MM+MCoherus works with Mark Cuban to sell biosimilar Humira at steep discounts STATThe Healthcare World According to Fein Managed Healthcare ExecutiveDrug Middlemen Accused of Price Fixing by Ohio Attorney General The Wall Street JournalDrugmakers push back on a clever tactic employers use to avoid paying for specialty medicines STATA Softbank-backed pharmacy startup is working to tackle a $300-billion-a-year prescription drug crisis FortuneTackling cancer while battling the insurance system The Washington Post 'It is legal extortion': Diabetics pay steep price for insulin as rebates drive up costs USA Today INDUSTRY NEWS AND BLOGS Drug Store News - Pharmacy Kiss Colors & Care serves as hair sponsor for Theophilio’s NYFW show STAT STAT+: Key Senate Republican throws cold water on Affordable Care Act repeal, site-neutral payment policy Fierce Pharma India's Zydus hit with warning letter as FDA flags glass contamination concerns and more Endpoints Innovent Biologics highlights subgroup of lung cancer patients in early-stage study of bispecific Biosimilars Review & Report The Last Domino Falls: OptumRx to Exclude Humira® From Some Drug Formularies Beginning January 2025 MMIT Network UnitedHealth Will Reduce Humira Coverage, Cover Stelara Biosimilar PR Newswire: Health Insurance Conduent Named a Leader in NelsonHall Healthcare Payer Operational Transformation Assessment PCMA PCMA Statement On House Judiciary Subcommittee Hearing Chain Drug Review CVS Health names Heidi Capozzi EVP, Chief People Officer RxTrace FDA’s Firm Stance on DSCSA Compliance: No More Delays Eye on FDA FDA Adds New AdComm to Address Genetic Metabolic Diseases The Catalyst (PhRMA) Three things to know from the latest Patient Experience Survey Health Business Group Interview with Aktana CEO David Ehrlich Show 10 Show All DISCLAIMERThe analyses on this website are based on information and data that are in the public domain. Any conclusions, findings, opinions, or recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by HMP Omnimedia, LLC, Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and HMP Omnimedia, LLC, Drug Channels Institute, and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. HMP Omnimedia, LLC, and Drug Channels Institute do not make investment recommendations, on this website or otherwise. Nothing on this website should be interpreted as an opinion by HMP Omnimedia, LLC, Drug Channels Institute, or the author on the investment prospects of specific companies. The comments contained on this site come from members of the public and do not necessarily reflect the views of Drug Channels Institute or the author. Neither Drug Channels Institute nor the author endorse or approve of their content. Drug Channels Institute and the author reserve the right to remove or block comments, but are under no obligation to explain individual moderation decisions. The public domain use of our materials includes linking to our website. You do not need to obtain special permission to link to the Drug Channels site. The material on this site is protected by copyright law. Unauthorized reproduction or distribution of this material may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This material may be cited in non-advertising commercial documents with full and appropriate attribution, but may not be used in any advertisements without prior written permission from Drug Channels Institute. We do not intend to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws. We do not permit our articles to be republished without prior written permission. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. Drug Channels® is a registered trademark of HMP Global. Privacy Policy | Terms of Use1729185721https://drugchannels.net

Modifier votre site ?

Que fais-tu?